{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:57:45Z","timestamp":1793775465071,"version":"4.6.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"20","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001491","name":"Belgian American Educational Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007229","name":"Special Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009550","name":"Hasselt University","doi-asserted-by":"publisher","award":["BOF19PD04"],"award-info":[{"award-number":["BOF19PD04"]}],"id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL128526"],"award-info":[{"award-number":["R01 HL128526"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A substantial proportion of patients with heart failure (HF) with preserved ejection fraction (HFpEF) present with normal natriuretic peptide (NP) levels. The pathophysiology and natural history for this phenotype remain unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Consecutive subjects undergoing invasive cardiopulmonary exercise testing for unexplained dyspnoea at Mayo Clinic in 2006\u201318 were studied. Heart failure with preserved ejection fraction was defined as a pulmonary arterial wedge pressure (PAWP) \u226515\u2005mmHg (rest) or \u226525\u2005mmHg (exercise). Patients with HFpEF and normal NP [N-terminal of the pro-hormone B-type natriuretic peptide (NT-proBNP) &amp;lt; 125\u2005ng\/L] were compared with HFpEF with high NP (NT-proBNP \u2265 125\u2005ng\/L) and controls with normal haemodynamics. Patients with HFpEF and normal (n = 157) vs. high NP (n = 263) were younger, yet older than controls (n = 161), with an intermediate comorbidity profile. Normal NP HFpEF was associated with more left ventricular hypertrophy and worse diastolic function compared with controls, but better diastolic function, lower left atrial volumes, superior right ventricular function, and less mitral\/tricuspid regurgitation compared with high NP HFpEF. Cardiac output (CO) reserve with exercise was preserved in normal NP HFpEF [101% predicted, interquartile range (IQR): 75\u2013124%], but this was achieved only at the cost of higher left ventricular transmural pressure (LVTMP) (14 \u00b1 6\u2005mmHg vs. 7 \u00b1 4\u2005mmHg in controls, P &amp;lt; 0.001). In contrast, CO reserve was decreased in high NP HFpEF (85% predicted, IQR: 59\u2013109%), with lower LVTMP (10 \u00b1 8\u2005mmHg) compared with normal NP HFpEF (P &amp;lt; 0.001), despite similar PAWP. Patients with high NP HFpEF displayed the highest event rates, but normal NP HFpEF still had 2.7-fold higher risk for mortality or HF readmissions compared with controls (hazard ratio: 2.74, 95% confidence interval: 1.02\u20137.32) after adjusting for age, sex, and body mass index.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with HFpEF and normal NP display mild diastolic dysfunction and preserved CO reserve during exercise, despite marked elevation in filling pressures. While clinical outcomes are not as poor compared with patients with high NP, patients with normal NP HFpEF exhibit increased risk of death or HF readmissions compared with patients without HF, emphasizing the importance of this phenotype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab911","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T20:37:00Z","timestamp":1640637420000},"page":"1941-1951","source":"Crossref","is-referenced-by-count":203,"title":["Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0599-9290","authenticated-orcid":false,"given":"Frederik H","family":"Verbrugge","sequence":"first","affiliation":[{"name":"Mayo Clinic Department of Cardiovascular Diseases, , Rochester, MN, USA"},{"name":"University Hospital Brussels Centre for Cardiovascular Diseases, , Brussels, Belgium"},{"name":"Hasselt University Faculty of Medicine and Life Sciences, Biomedical Research Institute, , Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Omote","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Cardiovascular Diseases, , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh N V","family":"Reddy","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Cardiovascular Diseases, , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Sorimachi","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Cardiovascular Diseases, , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5473-0688","authenticated-orcid":false,"given":"Masaru","family":"Obokata","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Cardiovascular Diseases, , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-0596","authenticated-orcid":false,"given":"Barry A","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Cardiovascular Diseases, , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"2022111105291477800_ehab911-B1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction","volume":"3","author":"Borlaug","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2022111105291477800_ehab911-B2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2022111105291477800_ehab911-B3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jchf.2018.03.003","article-title":"Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction","volume":"6","author":"Reddy","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2022111105291477800_ehab911-B4","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2022111105291477800_ehab911-B5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the universal definition of heart failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022111105291477800_ehab911-B6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction","volume":"110","author":"Anjan","year":"2012","journal-title":"Am J Cardiol"},{"key":"2022111105291477800_ehab911-B7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ahj.2012.08.014","article-title":"Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction","volume":"164","author":"Bishu","year":"2012","journal-title":"Am Heart J"},{"key":"2022111105291477800_ehab911-B8","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"van Veldhuisen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022111105291477800_ehab911-B9","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022111105291477800_ehab911-B10","doi-asserted-by":"crossref","first-page":"1700578","DOI":"10.1183\/13993003.00578-2017","article-title":"An official European Respiratory Society statement: pulmonary haemodynamics during exercise","volume":"50","author":"Kovacs","year":"2017","journal-title":"Eur Respir J"},{"key":"2022111105291477800_ehab911-B11","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2022111105291477800_ehab911-B12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2022111105291477800_ehab911-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2022111105291477800_ehab911-B14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2022111105291477800_ehab911-B15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"2022111105291477800_ehab911-B16","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/eurheartj\/ehw241","article-title":"Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction","volume":"37","author":"Borlaug","year":"2016","journal-title":"Eur Heart J"},{"key":"2022111105291477800_ehab911-B17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","article-title":"The role of the pericardium in heart failure: implications for pathophysiology and treatment","volume":"7","author":"Borlaug","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022111105291477800_ehab911-B18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/eurjhf\/hft026","article-title":"Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction","volume":"15","author":"Abudiab","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2022111105291477800_ehab911-B19","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2022111105291477800_ehab911-B20","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/eurheartj\/ehab082","article-title":"The struggle towards a universal definition of heart failure\u2014how to proceed?","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2022111105291477800_ehab911-B21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2022111105291477800_ehab911-B22","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2022111105291477800_ehab911-B23","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2022111105291477800_ehab911-B24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jchf.2019.12.010","article-title":"Natriuretic peptides as inclusion criteria in clinical trials: a JACC: heart failure position paper","volume":"8","author":"Ibrahim","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022111105291477800_ehab911-B25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"2022111105291477800_ehab911-B26","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"2022111105291477800_ehab911-B27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2013.04.070","article-title":"Abdominal contributions to cardiorenal dysfunction in congestive heart failure","volume":"62","author":"Verbrugge","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022111105291477800_ehab911-B28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/CIRCULATIONAHA.119.045409","article-title":"Altered hemodynamics and end-organ damage in heart failure: impact on the lung and kidney","volume":"142","author":"Verbrugge","year":"2020","journal-title":"Circulation"},{"key":"2022111105291477800_ehab911-B29","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction","volume":"40","author":"Reddy","year":"2019","journal-title":"Eur Heart J"},{"key":"2022111105291477800_ehab911-B30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2022111105291477800_ehab911-B31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/20\/1941\/46952699\/ehab911.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/20\/1941\/46952699\/ehab911.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:29:35Z","timestamp":1668144575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/20\/1941\/6525335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":31,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,2,9]]},"published-print":{"date-parts":[[2022,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab911","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,21]]},"published":{"date-parts":[[2022,2,9]]}}}